VBWG
Data alert

New data on optimal BP lowering in CAD patients: CAMELOT

The results of the Comparison of Amlodipine vs Enalapril to Limit Occurrence of Thrombosis (CAMELOT) study have recently been published.1 CAMELOT provides new data on optimal blood pressure (BP) levels and drug therapy for patients with coronary artery disease (CAD).

Deaths from cardiovascular (CV) disease have increased by 2.5% per year over the last decade.2 Deaths from heart disease are projected to increase a total of 128.5% between 2000 and 2050.3 In the next 50 years, deaths due to heart disease are projected to increase more than 2.5 times the growth of population.

Preventable major risk factors contribute to the global burden of heart disease. These include hypertension (49%) and hypercholesterolemia (56%), which together with obesity, physical inactivity, low fruit and vegetable intake, and tobacco use account for more than 80% of global morbidity and mortality from heart disease.4

References are listed at the end of the Data Alert.





Growth in heart disease, 2000–2050

Download 05-DA-CAMELOT.ppt (12 slides - 0.4MB)

Growth in heart disease, 2000–2050 Burden of adult hypertension CAMELOT: Optimal BP control in CAD patients CAMELOT: Baseline characteristics and concomitant medications CAMELOT: Similar BP reductions frombaseline with amlodipine and enalapril CAMELOT: 31% Reduction in primary outcome with amlodipine compared to standard care CAMELOT: Reduction in primary outcome
with amlodipine, by subgroup CAMELOT: Slowed progression of atheroma with amlodipine and enalapril CAMELOT: Continuous relationship between rate of atheroma progression and change in SBP INVEST: Similar BP control with CAS and NCAS in hypertensive CAD patients INVEST: Similar reduction in primary outcome 
with CAS and NCAS in CAD patients CAMELOT: Conclusions
Data_Alert.pdf (1.5MB)Data_Alert.pdf (1.5MB)


AmlodipineCADCAMELOTComparisonEnalaprilLimitpublishedThrombosis

Related at vwbg.org

Core Curriculum

Myocardial Ischemia Redefined: Optimal Care in CAD

View/Download individual slides (90 Slides)

Vascular Biology in Clinical Practice © Vol. 7, No. 1

ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection

This monograph, ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection , which is being offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.
More related